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Introduction
Cutaneous T cell lymphomas (CTCLs) are the most frequent lymphomas occurring in the skin. 1 Mycosis fungoides (MF), and its leukemic variant, Sezary syndrome (SS), are the most common representatives of CTCL (reviewed in Ref. 2) . CTCL tumor cells are activated in vitro through antigen-independent pathways such as the CDw60 and the interleukin-2 (IL-2) pathways [3] [4] [5] and tumor cells obtained from skin and blood from CTCL patients often express high levels of the IL-2 highaffinity receptor (IL-2R␣␤␥). [6] [7] [8] [9] In contrast, peripheral blood T lymphocytes from healthy individuals do not express IL-2 high-affinity receptors and IL-2R␣ expression (and IL-2 sensitivity) is strictly regulated in nonmalignant T cells. Thus, only upon antigen receptor stimulation peripheral blood T cells are induced to express IL-2R␣ and undergo IL-2-driven growth (reviewed in Ref. 10) . 11 At present, it is poorly understood why IL-2R␣ is highly expressed on many CTCL tumor cell lines. However, recently it was shown that STAT3, a member of signal transducers and activators of transcription (STAT), was constitutively phosphorylated on tyrosine in MF tumor cell lines, but not in autologous, nonmalignant T cells. 12 This together with the recent finding that STAT3-deficient T cells show impaired IL-2-mediated IL-2R␣ chain expression 13 might indicate that STAT3 is involved in the regulation of IL-2R␣ in CTCL. In a recent study by Zhang et al, 8 STAT3 was also found to be constitutively phosphorylated in cell lines obtained from a patient with advanced CTCL and notably, the IL-2R complex was expressed at high levels and appeared to be constitutively tyrosine phosphorylated suggesting that IL-2R dysregulation might be an important feature of at least some CTCL tumors. 8 In nonmalignant T cells, cytokine and growth factor receptor-associated Janus kinases (JAKs) become activated by tyrosine (auto)phosphorylation upon receptor ligation (reviewed in Ref. 14) . Once activated the JAKs tyrosine phosphorylate latent cytoplasmic STATs. This tyrosine phosphorylation mediates homo-or heterodimerization of STAT-proteins, which then translocate to the nucleus, where they function as transcription factors. The present investigation was undertaken to study STAT activation and its possible link to constitutive IL-2R␣ expression in a leukemic cell line obtained from peripheral blood of a patient with SS.
Materials and methods

Antibodies and other reagents
Recombinant IL-2 was a generous gift from Craig W Reynolds (Biological Response Modifiers Program, National Cancer Institute, Bethesda, MD, USA). Recombinant IFN-␣ (Introna) was from Schering-Plough (Kenilworth, NJ, USA). Recombinant human IL-4 and fluorescein isothiocyanate (FITC) conjugated anti-CD2 (LFA-2) monoclonal antibody (mAb) was purchased from Leinco Technologies (St Louis, MO, USA). Anti-IL-2R␣ mAb conjugated with phycoerythrin (PE) was from Becton Dickinson (San Jose, CA, USA). (For each specific Ab the corresponding FITC or PE conjugated isotype control antibody was used.) Phosphospecific STAT1 (Tyr701), STAT3 (Tyr705), STAT5 (Tyr694), and STAT6 (Tyr641) polyclonal antibody (pAb) were from New England Biolabs (Beverly, MA, USA). STAT1, STAT6, ERK-2, JAK1, JAK3, and TYK2 pAb were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). STAT3 and STAT5 pAb were from Transduction Laboratories (Lexington, KY, USA). Anti-Phosphotyrosine mAb (4G10) was from Upstate Biotechnology (Lake Placid, NY, USA). DNA binding dye 7-amino-actinomycin D (7-AAD) was from Sigma (St Louis, MO, USA). Tyrphostin AG490 and tyrphostin AG1478 were from Alexis Corporation (Lausen, Switzerland). The enhanced chemiluminescense (ECL) kit was from Amersham (Little Chalfont, UK). The ribonuclease protection kit and the in vitro transcription kit was from Pharmingen (San Diego, CA, USA). The double-stranded STAT-binding sequence from the IL-2R␣-promotor used for affinity purification was 5Ј-Bio-ACATTTC TGATAATAGAATT-3Ј.
Leukemia
Cells
A continuous tumor cell line, Se-Ax, was established from the peripheral blood from a patient with SS as described in detail elsewhere. 4, 16 Malignant (MyLa1924 and MyLa2039) and nonmalignant (MyLa1885) CD4 + T cell lines were established from a plaque biopsy specimen of a patient with MF as described in detail elsewhere. 17 A combinatorial approach that included phenotyping, genotyping, HLA-typing, and karyotyping verified the cell origin of these cell lines. 17 Alloantigen-specific human CD4
+ T cell lines were obtained from healthy donors and have been described. 18 The Jurkat cell line is a continuously growing leukemic T cell line. The JY cell line is an Epstein-Barr virus (EBV) transformed B cell line. Cells were cultured in RPMI 1640 (Sigma) supplemented with either 10% pooled human serum (HS) (Bloodbank, State University Hospital, Copenhagen, Denmark) (SS, MF, and alloantigen-specific CD4 + T cells) or 10% fetal calf serum (Life Technologies, Tåstrup, Denmark) (Jurkat and JY cells), 2 mM L-glutamine (Sigma), 100 g/ml penicillin (Sigma), 100 g/ml streptomycin (Sigma), 1000 U/ml IL-2 (SS, MF and alloantigen-specific CD4 + T cells), and 10 ng/ml IL-4 (MF cells). SS cells, MF cells, and alloantigen-specific CD4 + T were washed twice and starved for IL-2 and IL-4 for 16-18 h before initiation of the experiments described below.
Proliferation assays
Assays were performed in culture medium (RPMI 1640) supplemented with 10% HS, 2 mM L-glutamine, 100 g/ml penicillin, 100 g/ml streptomycin, and 1000 U/ml IL-2 in 96-well round-buttom tissue culture plates (Nunc, Roskilde, Denmark) with a final volume of 200 l. 18 18 
Oligonucleotide affinity purification or immunoprecipitation of JAK/STAT proteins and Western blotting
For analysis of total lysates 1.5 × 10 6 cells/experiment and 20 × 10 6 cells/experiment for oligonucleotide affinity purification and immunoprecipitation were lysed in ice cold lysis buffer (1% NP-40, 20 mM Tris pH 8.0, 137 mM NaCl, 5 mM MgCl 2 , 10% glycerol and the following inhibitors: 5 mM EDTA, 1 mM Na 3 VO 4 , 10 g/ml aprotinin, 4 M iodoacetamide, and 1 mM phenylmethylsulfonyl fluoride (PMSF)). For oligonucleotide affinity purification or immunoprecipitation, cellular lysates were precleared for 2 h using streptavidin-or protein A-conjugated beads, respectively. Next, 150 pmol of double-stranded biotinylated oligonucleotide (affinity purification) or 2.5 mg anti-JAK-Abs/7 mg anti-phosphotyrosine-Ab (immunoprecipitation) was added to 1 ml of precleared cellular lysate and samples were rotated overnight at 4°C. STAT/oligonucleotide-or protein/Ab complexes were recovered using streptavidin-or protein A-conjugated beads, respectively, while rotating samples for 90 min. The immunoprecipitated proteins were pelleted and washed five times in lysis buffer. Purified proteins or total lysates were boiled in reducing SDS sample buffer and analyzed by gel electrophoresis followed by electrophoretic transfer to a nitrocellulose membrane. The membrane was blocked in 3% skimmed powder milk, 1% BSA in PBS and incubated with primary Ab in blocking buffer followed by washing in PBS and incubation with peroxidase conjugated secondary antibody. Blots were evaluated using enhanced chemiluminescence (ECL), stripped and reprobed according to the manufacturer's manual (Amersham).
FACS analysis of cell surface expression
Cells were harvested (5 × 10 5 ), washed three times in washing buffer (PBS, 5% FCS, 0.1% sodium azide), and pelleted. The cells were resuspended in 4 l labeled Ab, vortexed and incubated for 30 min at 4°C in the dark. The cells were washed three times in washing buffer and stored at 4°C in the dark until they were analyzed on FACScan (Becton Dickinson). 10 4 cells per sample were analyzed.
Quantification of apoptotic cells
Apoptotic cells were quantified by the use of the DNA binding dye 7-amino-actinomycin D (7-AAD). Cells were harvested (5 × 10 5 ), washed once in washing-buffer (PBS, 5% FCS, 0.1% sodium azide), resuspended in 0.5 ml 0.05% saponin in PBS, and pelleted. The cells were resuspended in 0.5 ml 4 g/ml 7-AAD in 0.05% saponin in PBS, incubated at room temperature in the dark in 30-45 min, and analyzed on a FACScan (Becton Dickinson). Untreated cells were used to set gates for viable cells with 2N-4N DNA, for apoptotic cells with subnormal DNA content, and for exclusion of debris.
RNAse protection assay
RNA extraction was performed using the QIAshredder and RNeasy Mini Kits from Qiagen (Hilden, Germany) according to the manufacturer's manual. The purity and size distribution of total RNA were determined by agarose gel electrophoresis. RNase protection assay was performed using the ribonuclease protection kit and the in vitro transcription kit according to the manufacturer's protocol (Pharmingen).
Results
STAT3 is constitutively tyrosine-phosphorylated in SS cells
To study STAT activation in SS tumor cells, total cell lysates were made from SS cells which had been washed twice, starved overnight in culture medium without IL-2, and subsequently stimulated with cytokines. The cell lysates were then analyzed by Western blotting by use of antibody against tyrosine-phosphorylated STAT3. As shown in Figure 1a , STAT3 is constitutively phosphorylated on tyrosine in the unstimulated starved cells. Subsequent stimulation with IL-2 or IL-4 induced an enhanced tyrosine phosphorylation of STAT3. In addition, IL-2 triggered a mobility shift of tyrosine phosphorylated STAT3 which was most likely caused by hyperphosphorylation of serine residues. 19 Stripping the membrane, and reprobing with an antibody against tyrosine phos- STAT3 is constitutively tyrosine-phosphorylated in SS cells. In (a), SS cells were washed twice in RPMI 1640 and starved in culture medium without IL-2 in 16-18 h. Cells were then stimulated with (+) or without (−) IL-2 (500 units/ml) or IL-4 (25 ng/ml) for 10 min and lysed. Total cell lysates were subjected to Western blotting using Ab recognizing tyrosine phosphorylated STAT3 (PY-STAT3). The same blot was subsequently stripped and reprobed three times with antibody against STAT3, PY-STAT5, and STAT5 respectively. In (b), SS cells were stimulated with or without IFN-␣ (5 × 10 3 units/ml) or IL-4 (25 ng/ml) for 10 min and analyzed by Western blotting using Abs against PY-STAT1, STAT1, PY-STAT6, and STAT6. In phorylated STAT5 showed that STAT5 was not tyrosinephosphorylated in unstimulated starved cells, whereas stimulation with IL-2 resulted in a clear induction of phosphotyrosine STAT5 (Figure 1a, lower panel) . This suggested that the constitutive tyrosine phosphorylation of STAT3 in tumor cells seemed to be specific and that other parts of the IL-2R signal pathway were not affected. To analyze how STATs other than those confined to the IL-2R signal pathway were activated in these cells, we stimulated starved SS cells with IFN-␣ and IL-4 which are known to activate STAT1 and STAT6, respectively. 20 As can be seen in Figure 1b , neither STAT1 nor STAT6 is constitutively activated in unstimulated starved cells. However, following IL-4 stimulation STAT6 (and to some extent STAT3 (Figure 1a) ) became activated. Likewise, IFN-␣ stimulation induced strong activation of STAT1 supporting the conclusions above that the constitutive phosphorylation of STAT3 is highly specific and that cytokine-mediated STAT activation (Figure 1c, upper panel) . Moreover, the amount per cell of total STAT3 was higher in SS cells as compared to the other T cells tested. In contrast, the amount per cell of the ERK-2 MAP kinase was comparable in malignant and nonmalignant cells suggesting that both the level of tyrosine phosphorylation and the total amount of STAT3 was higher in SS cells than in nonmalignant T cells. STAT3 tyrosine phosphorylation in SS cells did however not appear to be a simple consequence of the high expression of STAT3 protein since STAT3 was not constitutively phosphorylated on tyrosine in EBV-transformed B cell lines which also express high levels of STAT3 protein (Figure 1c) . Furthermore constitutive tyrosine phosphorylation of STAT3 was readily detectable in SS cells but not in nonmalignant T cells in analysis of equal amounts of STAT3 from SS and the other T cells tested (data not shown).
Janus kinase 3 (JAK3) is constitutively tyrosine phosphorylated in SS cells
Janus kinases are believed to be responsible for tyrosine phosphorylation of STATs in response to growth factors 14 and the constitutive activation of STAT3 in CTCL cells correlated with a constitutive JAK3 activation and/or a co-association between JAK3 and STAT3. 8, 12 Accordingly, we addressed whether JAK3 was constitutively tyrosine phosphorylated in SS cells and as shown in Figure 2a (middle panel), JAK3 was constitutively phosphorylated on tyrosine as judged from immunoblotting of immunoprecipitated JAK3 with an anti-phosphotyrosine antibody. In contrast, neither JAK1 nor TYK2 were phosphorylated on tyrosine (Figure 2a , left and right panels). To confirm that JAK3 was constitutively tyrosine phosphorylated, phosphotyrosine proteins were immunoprecipitated from an independent culture of SS cells and subjected to Western blotting with anti-JAK3 antibody and as expected both JAK3 and STAT3 were constitutively tyrosine phosphorylated ( Figure  2b ). Pre-incubation of live cells with an inhibitor of Janus tyrosine kinases, tyrphostin AG490, inhibited tyrosine phosphorylation of JAK3 (Figure 2c) indicating that the constitutive activation of JAK3 in SS cells is sensitive to inhibition with tyrphostin AG490.
AG490 inhibits constitutive STAT3 activation
It was previously shown 12, 21 that the constitutive activation of STAT3 in malignant T cell lines established from a patient with MF was inhibited by tyrphostin AG490. To examine whether JAK3 might be responsible for the constitutive tyrosine phosphorylation of STAT3 in SS cells, washed SS cells were incubated in culture medium without IL-2 overnight with different concentrations of AG490 or tyrphostin AG1478, an inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase. DMSO, the solvent used to dissolve AG490 and AG1478, was added subsequently to equalize the amount of solvent in each sample. The samples were then lysed and analyzed by Western blotting with anti-phosphotyrosine STAT3 antibody as described above. As shown in Figure 3 (upper lane, left) , AG490 clearly inhibited the constitutive phosphorylation of STAT3 at concentrations of 50 M and above. In contrast, AG1478 showed no inhibition of the constitutive tyrosine phosphorylation of STAT3 (Figure 3 , upper lane, right), even at concentrations which fully block the EGF receptor kinase 22 and EGF-induced STAT3 activation (data not shown). DMSO had no toxic effect on the constitutively activated STAT3. To verify that equal amounts of STAT3 were present in each sam-
Figure 2
JAK3 is constitutively tyrosine-phosphorylated in SS cells. SS cells were starved overnight, lysed, and JAK-proteins (a) or tyrosine phosphorylated proteins (b and c) were subsequently immunoprecipitated using Abs recognizing JAK1, JAK2, JAK3, and TYK2 or phosphotyrosine (P-Tyr), respectively. In (c), live cells were incubated with or without tyrphostin AG490 or DMSO as control prior to immunoprecipitation with anti-phosphotyrosine antibody (see Materials and methods). 
Inhibition of phosphotyrosine STAT3 by AG490 triggers a down-regulation of IL-2R␣
STAT3 is a transcription factor known to regulate transcriptional activity of the IL-2R␣ gene. 13 Since tyrosine phosphorylation of STAT3 is a prerequisite for STAT3 homodimerization and transcriptional activity, 20 we took advantage of the STAT3 inhibitor, AG490, to address whether STAT3 was involved in the constitutive expression of IL-2R␣. Accordingly, prewashed SS tumor cells were incubated with or without AG490 in culture medium without IL-2 overnight prior to affinity purification with a biotinylated oligonucleotide probe representing a STAT3-binding sequence from the IL-2R␣ promoter. As expected, STAT3 spontaneously bound to the IL-2R␣ promoter (Figure 4a ) confirming that STAT3 is constitutively activated in SS cells. Reprobing with antibodies against STAT5 showed no significant binding (data not shown) supporting our findings above of a selective dysregulation of STAT3 activation. AG490 inhibited DNA-binding of STAT3 to the IL-2R␣-probe in a dose-dependent manner, ie AG490 inhibited tyrosine phosphorylation and DNA-binding in parallel. To address whether inhibition of DNA-binding correlated with inhibition of transcription, RNAse protection assays were performed on cells treated as above and as shown in Figure 4b , AG490 inhibited the constitutive expression of IL-2R␣ mRNA in a dose-dependent manner. Next, a flow cytometric analysis of the surface expression of IL-2R␣ was done after AG490 treatment of SS cells. As shown in Figure 4c , AG490 induced a significant down-regulation of IL-2R␣ expression. In contrast, AG490 did not induce down-regulation of CD2 expression suggesting that AG490 had a selective effect on IL-2R␣ expression (Figure 4c ). To address whether a similar effect of AG490 was observed in other CTCL tumor lines expressing a constitutively activated STAT3, 'early' tumor cell lines (MyLa1929 and MyLa2039) from affected skin of a MF patient 4, 12 were treated with AG490 as above prior to examination for IL-2R␣ expression. In both cell lines, AG490 induced a similar dose-dependent inhibition of IL-2R␣ expression (data not shown). As the turnover of phosphotyrosine STAT3 appears to be slow in CTCL tumor cells, 19 SS cells were grown for longer periods of time with or without AG490 prior to flow cytometric analysis and as shown in Figure 4d , AG490 had a
Figure 4
Inhibition of phosphotyrosine STAT3 by AG490 triggers down-regulation of IL-2R␣. SS cells were incubated with or without the indicated concentrations of AG490 in culture medium without IL-2 and with each sample containing equal amounts of DMSO (solvent). The incubation time for each experiment is described below. In (a), SS cells were lysed after incubation overnight. DNA-binding STAT proteins were then affinity-purified using a biotinylated probe and analyzed by Western blotting with STAT3 Ab. In (b), cell cultures were incubated overnight with AG490, AG1478, or DMSO and subsequently subjected to quantification of IL-2R␣ mRNA expression using RNAse protection assay as described in Materials and methods. Data are shown for radiolabeled antisense RNA probes specific for IL-2R␣-messenger RNA (mRNA) and to mRNA for the housekeeping protein, GADPH (glyceraldehyde-3-phosphate dehydrogenase). In (c), cell cultures incubated overnight were subsequently subjected to quantification of IL-2R␣ and CD2 expression by FACS analysis as described in Materials and methods. The expression of IL-2R␣ and CD2 is indicated as mean fluorescence intensity (MFI). In cumulative inhibitory effect on IL-2R␣ expression. Thus, after 3 days of culture IL-2R␣ expression had dropped by more than 80% (Figure 4d ).
Inhibition of STAT3 activity and IL-2R␣ expression is followed by growth inhibition and induction of apoptosis
IL-2 triggers mitogenesis, sustains prolonged growth, and inhibits apoptosis in T cells through activation of the JAK-STAT signal pathway (reviewed in Refs 10 and 23). From studies in STAT3-deficient T cells from transgenic mice, 13 it has been hypothesized that STAT3 is involved in a positive feed-back regulation of the expression of IL-2 high-affinity receptors: IL-2R ligation triggers STAT3 activation which leads to IL-2R␣ gene transcription and IL-2R␣ surface expression which in turn increases IL-2 sensitivity, signal transduction, and proliferation of antigen stimulated T cells. 13 As shown in Figure  5a , AG490 induced a time-dependent growth inhibition of IL-2-stimulated SS cells. The inhibition was also dose-dependent (data not shown). In contrast, the EGF receptor tyrosine kinase inhibitor, AG1478, had no inhibitory effect on the growth of SS tumor cells. AG490 did not inhibit mitogenesis for the first 24 h of culture (Figure 5a ), ie the effect on IL-2R␣ mRNA and protein expression (Figure 4 ) preceded the effect on mitogenesis, suggesting that growth inhibition might be secondary to Leukemia the inhibition of STAT3 and IL-2R␣. As mentioned above, IL-2 and JAK-STAT signalling have been implicated in the regulation of apoptosis in cytokine-stimulated T cells and in MF tumor cells. 10, 21, 23, 24 Accordingly, we addressed whether AG490-mediated STAT3 and IL-2R␣ inhibition was associated with an inhibition of survival signals and a subsequent induction of apoptosis in SS tumor cells. Indeed, AG490 induced a concentration-and time-dependent increase in apoptosis in SS tumor cells (Figure 5b ). In contrast, AG1478 had little effect on apoptosis in SS tumor cells (data not shown).
Discussion
In the present study, we provide the first example of a constitutive STAT3 activation in a tumor cell line established from peripheral blood of a SS patient. 16 Thus, high levels of phosphotyrosine STAT3 was detected in cytokine-deprived SS tumor cells, but not in nonmalignant T cells. Other STAT proteins were not constitutively phosphorylated in cytokinedeprived tumor cells. Yet, upon cytokine stimulation tyrosine phosphorylated proteins other than STAT3 were detected in the SS tumor cells. Thus, phosphotyrosine STAT1, STAT5 and STAT6 were induced following stimulation with IFN-␣, IL-2, and IL-4, respectively. Taken together, these data suggest that the SS tumor cell line has a selective and highly specific dysregulation of STAT3 (but not of other STATs). In two recent stud-
Figure 5
Inhibition of STAT3 activity and IL-2R␣ expression is followed by growth inhibition and induction of apoptosis. SS cells were cultured with or without AG490, AG1478 or medium containing the relevant amount of DMSO (solvent) for the indicated periods of time. Cell cultures were subsequently subjected to (a) [ ies of CTCL, STAT3 was found to be constitutively activated in tumor cell lines obtained from independent specimens from affected skin of a MF patient 12 and in a tumor cell line obtained from a patient with advanced CTCL. 8 In the latter study, phosphotyrosine STAT3 was also seen in tumor cells isolated directly from the blood of SS patients. However, following cytokine deprivation phosphotyrosine STAT3 disappeared from the cytosol in these tumor cells suggesting that STAT3 activation was not caused by an intrinsic dysregulation but rather induced by cytokines or growth factors in vivo. 8 In contrast, tyrosine phosphorylated STAT3 did not disappear from the cytosol following cytokine deprivation of SS tumor cells. Indeed, high levels of tyrosine phosphorylated STAT3 was observed following cytokine deprivation of SS tumor cells. At present, we are unable to explain these differences. One explanation might be that a constitutive STAT3 activation is a marker of lymphoma progression in CTCL. Thus, STAT3 was strongly activated in tumor cell lines obtained from affected skin of a patient with late-stage MF, whereas only weak STAT3 activation was observed in a tumor cell line obtained from an earlier skin specimen from the same MF patient. 12 In support of this possibility, Zhang et al 8 observed a constitutive STAT3 activation in tumor cells obtained from a patient with advanced (anaplastic) CTCL. Moreover, a modified form of STAT3, which spontaneously forms a transcriptionally active STAT3 homodimer, was recently shown to function as an oncogene in vivo in experimental animals. 25 Taken together these data support the idea that STAT3 might play a role in the pathogenesis of advanced stages of CTCL. Since a constitutive activation of STAT3 has also been described in other clinical cancers, it is possible that dysregulation of STAT3 might have a more general role in malignant transformation.
STAT3 is a transcription factor involved in regulation of several genes including c-fos and ICAM-1. 26 Recently, it was shown that STAT3 binds to the promotor of the IL-2R␣ gene 27 and STAT3-deficient T cells from transgene animals showed a decreased IL-2R␣ expression in response to antigen and IL-2.
13 CTCL tumor cell lines usually express high levels of IL-2R␣ and the present observation that AG490-mediated STAT3 inhibition was accompanied by a gradually decreased IL-2R␣ expression and IL-2-sensitivity supported the possibility that STAT3 activation is implicated in the aberrant expression of IL-2R␣ in CTCL. It is a characteristic feature of CTCL that cytokine-producing inflammatory T cells infiltrate tumor lesions. 28 The present findings prompt us to hypothesize that a constitutive STAT3 activation triggers an aberrant expression of cytokine receptors such as IL-2R␣. Thus, STAT3 activation might indirectly increase tumor sensitivity to cytokines produced locally and thus increase tumor growth in vivo.
In conclusion, we provide the first example of a constitutive STAT3 activation in SS tumor cells. Thus, our data support the idea that STAT3 activation is involved in human cancer.
